US Has Opportunity To Lead On Ophthalmic Biosimilars
Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report
With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology – in an exclusive interview with Generics Bulletin.
You may also be interested in...
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.
A balanced policy environment that supports competition is needed to allow biosimilars to flourish in the US, according to Amgen, along with strong and transparent IP processes to underpin continuing innovation in the biologics space. Chad Pettit, the firm’s executive director of marketing and global biosimilars commercial lead, talks to Generics Bulletin about the firm’s “unique perspective” on biosimilars.
Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.